The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials
| Autor: | Xiang-Qi Chen, Lan-Lan Lin, Guofu Lin, Qiong Luo |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Risk
0301 basic medicine medicine.medical_specialty Lung Neoplasms Programmed Cell Death 1 Receptor Immunology Antineoplastic Agents Gastroenterology B7-H1 Antigen law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Carcinoma Non-Small-Cell Lung Internal medicine medicine Animals Humans Immunology and Allergy Colitis Adverse effect Lung cancer Randomized Controlled Trials as Topic Pharmacology business.industry Incidence Incidence (epidemiology) medicine.disease Clinical trial Diarrhea 030104 developmental biology 030220 oncology & carcinogenesis Relative risk medicine.symptom business |
| Zdroj: | International Immunopharmacology. 77:105975 |
| ISSN: | 1567-5769 |
| DOI: | 10.1016/j.intimp.2019.105975 |
| Popis: | BACKGROUND The programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors have shown encouraging merits in non-small cell lung cancer (NSCLC) patients, however, they are often related to potentially fatal immune-related adverse events (irAEs) including colitis. Considering the incidence and characteristics of immune-related colitis may have significant implications for the appropriate utilization of PD-1/PD-L1 inhibitors in clinical practice, we conduct this meta to systematically analyze the correlation between PD-1/PD-L1 inhibitors for the treatment of NSCLC and the incidence of immune-associated colitis. METHODS Electronic databases including PubMed, Embase, Cochrane Library and ClinicalTrials.gov (http://clinicaltrials.gov/) were searched up to May 2019, clinical trials reporting all grade (1-5), higher grade (3-5) colitis and grade 3-5 diarrhea were included, data were expressed as relative risk (RR), incidence, corresponding p value and 95% confidence intervals (CIs). RESULTS 9 randomized controlled trials (RCTs) were identified (7 with PD-1 inhibitors [n = 4526]) and 2 with PD-L1 inhibitors [n = 1464]). The overall incidence of PD-1/PD-L1 target agents was 1.40% for all grade colitis, 0.89% for severe colitis, 11.62% for all grade diarrhea and 1.36% for severe diarrhea. Compared with chemotherapy group, the PD-1/PD-L1 inhibitors had a significantly higher risk of all grade (RR: 3.68, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect